AlphaCore Capital LLC Acquires Shares of 4,276 The Clorox Company (NYSE:CLX)

AlphaCore Capital LLC acquired a new position in shares of The Clorox Company (NYSE:CLX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,276 shares of the company's stock, valued at approximately $694,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Mackenzie Financial Corp lifted its position in shares of Clorox by 30.5% during the 4th quarter. Mackenzie Financial Corp now owns 13,464 shares of the company's stock worth $2,187,000 after buying an additional 3,148 shares during the last quarter. Ball & Co Wealth Management Inc. bought a new position in Clorox in the fourth quarter valued at about $139,000. Public Employees Retirement System of Ohio raised its position in Clorox by 0.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 60,035 shares of the company's stock valued at $9,750,000 after purchasing an additional 269 shares during the last quarter. Pacific Point Advisors LLC bought a new position in Clorox in the fourth quarter valued at about $1,265,000. Finally, Vise Technologies Inc. bought a new position in Clorox in the fourth quarter valued at about $250,000. 78.53% of the stock is currently owned by institutional investors.

Clorox Trading Down 0.4%

NYSE CLX traded down $0.58 during trading hours on Tuesday, hitting $130.30. 2,190,099 shares of the company's stock were exchanged, compared to its average volume of 1,337,366. The stock has a 50-day simple moving average of $139.35 and a 200 day simple moving average of $152.00. The Clorox Company has a 1-year low of $127.60 and a 1-year high of $171.37. The firm has a market cap of $16.06 billion, a price-to-earnings ratio of 35.60, a PEG ratio of 2.62 and a beta of 0.60. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same period in the prior year, the business earned $1.71 EPS. The company's revenue for the quarter was down 8.0% on a year-over-year basis. On average, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the purchase, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.57% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. JPMorgan Chase & Co. dropped their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Barclays dropped their target price on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $150.00 target price on shares of Clorox in a research report on Thursday, January 30th. Wells Fargo & Company dropped their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Citigroup dropped their target price on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.